Welcome to ourAnnual Report 2020

Letter from
the management

We are turning the page on an eventful and challenging year. At the same time, 2020 also brought us important scientific and commercial progress and opportunities, and we are confident that we are well positioned to build on our strengths going forward. Onno van de Stolpe, CEO
Letter from the management

Financial highlights

Group revenues

Group revenues

530.3 million
Read more

Cash position

Cash position

5169.3 million
Read more

Deferred income

Deferred income

2809.1 million
Read more

R&D expenditure

R&D expenditure

523.7 million
Read more

Magazine

Expanding our approach to target discovery

In the search for potential starting points for new medicines, Galapagos scientists have so far been able to work with six thousand potential targets. With a new approach, this potential has been expanded to twenty thousand starting points. “By using a more targeted search in a much larger haystack, we can find the best needles more successfully,” says CSO Piet Wigerinck.

Read more

Embarking on an era of patient partnership

At Galapagos, we do everything with patients in mind because in the end, our work is all about improving people’s quality of life.

Read more

A landmark year for our
commercial colleagues

In 2020, Galapagos brought its first medicine to patients in Europe. It was the year that saw the commercial side of our business step into the spotlight. We spoke to team leaders Michele Manto and Emma Chaffin, who told us the story from both a global and local perspective. Hear about the year’s activities, its highlights and their vision for the future.